Aclarion, Inc. ACON
leverages Magnetic Resonance Spectroscopy ("MRS"), and proprietary biomarkers to optimize clinical treatments. Aclarion's
technology addresses the $134.5B U.S. low back and neck pain market, which according to a 2020 JAMA (Journal of the American Medical Association)
article is now the most costly healthcare condition in the United States. The Company is currently utilizing Artificial Intelligence ("AI")
to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. The use of AI in this application is
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $75.7K | $45.7K | $75.4K | $60.4K | $60.3K | — |
| Cost of revenue | $68.9K | $84.7K | $75.7K | $65.3K | $69.2K | — |
| Gross profit | $6.8K | -$38.9K | -$324 | -$4.9K | -$8.9K | — |
| R&D | $1.0M | $888.8K | $873.3K | $1.1M | $787.9K | — |
| SG&A | $4.1M | $3.6M | $3.2M | $4.0M | $1.8M | — |
| Total operating expenses | $7.1M | $5.5M | $4.9M | $5.6M | $2.9M | — |
| Operating income | -$7.1M | -$5.5M | -$4.9M | -$5.6M | -$3.0M | — |
| Interest expense | — | $64.1K | $110.5K | $1.5M | $474.9K | — |
| Pre-tax income | -$7.2M | -$7.0M | -$4.9M | -$7.1M | -$5.0M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$7.2M | -$7.0M | -$4.9M | -$7.1M | -$5.0M | — |
| EPS, basic | -13.61 | -7,478.90 | -79,782.00 | -19.61 | -6.58 | — |
| EPS, diluted | -13.61 | -7,478.90 | -79,782.00 | -19.61 | -6.58 | — |
| Shares, diluted (wtd. avg.) | 532,036 | 943 | 62 | 381,598 | 905,685 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $12.0M | $453.7K | $1.0M | $1.5M | $452.5K | $15.0K |
| Receivables | $29.7K | $18.3K | $13.3K | $18.6K | $6.3K | — |
| Total current assets | $12.4M | $824.3K | $1.3M | $1.7M | $732.2K | — |
| Property, plant and equipment | $24.2K | $5.5K | $1.8K | $3.3K | $12.6K | — |
| Other intangibles | $1.3M | $1.3M | $1.2M | $1.2M | $1.1M | — |
| Total assets | $13.7M | $2.1M | $2.5M | $2.9M | $1.9M | — |
| Accounts payable | $333.0K | $531.6K | $760.5K | $462.2K | $1.1M | — |
| Total current liabilities | $837.3K | $1.2M | $3.2M | $688.7K | $7.6M | — |
| Total liabilities | $837.3K | $1.2M | — | — | — | — |
| Retained earnings | -$58.5M | -$51.3M | -$44.3M | -$39.4M | -$31.9M | — |
| Total equity | $12.8M | $970.1K | -$728.0K | $2.2M | -$12.8M | -$7.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.2M | -$5.3M | -$3.6M | -$4.9M | -$2.4M | — |
| Depreciation and amortisation | $227.4K | $193.1K | $162.7K | $4.5K | $13.0K | — |
| Stock-based compensation | $105.4K | $287.5K | $456.0K | $1.2M | $177.5K | — |
| Capital expenditure | $21.5K | $5.1K | $0 | — | — | — |
| Investing cash flow | -$203.9K | -$321.9K | -$119.5K | -$207.9K | -$102.0K | — |
| Financing cash flow | $18.9M | $5.0M | $3.3M | $6.2M | $2.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-26-001986.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $60.3K | $60.4K | $75.4K | $45.7K | $75.7K |
| Gross profit | — | -$8.9K | -$4.9K | -$324 | -$38.9K | $6.8K |
| Net income | — | -$5.0M | -$7.1M | -$4.9M | -$7.0M | -$7.2M |
Recent filings and events
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
- Material agreement signed Item 1.01
- Material agreement signed Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $58.23B | — | 35.9% |
| DGX | QUEST DIAGNOSTICS INC | $26.70B | 27.6x | 11.8% |
| LH | LABCORP HOLDINGS INC. | $26.68B | 31.4x | 7.2% |
| GH | Guardant Health, Inc. | $22.69B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $9.04B | — | 97.0% |
| GRAL | GRAIL, Inc. | $5.92B | — | 17.2% |
| RDNT | RadNet, Inc. | $5.54B | — | 11.5% |
| BLLN | BillionToOne, Inc. | $5.00B | 769.8x | 100.0% |